Solid cancer: the new tumour spread endpoint opens novel opportunities
Language English Country Great Britain, England Media print-electronic
Document type Editorial, Research Support, Non-U.S. Gov't
PubMed
31427682
PubMed Central
PMC6889500
DOI
10.1038/s41416-019-0536-0
PII: 10.1038/s41416-019-0536-0
Knihovny.cz E-resources
- MeSH
- Androgen Antagonists therapeutic use MeSH
- Benzamides MeSH
- Drug Resistance, Neoplasm genetics MeSH
- Progression-Free Survival MeSH
- Phenylthiohydantoin analogs & derivatives therapeutic use MeSH
- Humans MeSH
- Neoplasm Metastasis diagnostic imaging prevention & control MeSH
- Prostatic Neoplasms, Castration-Resistant blood diagnostic imaging drug therapy pathology MeSH
- Nitriles MeSH
- Cell Movement drug effects MeSH
- Disease Progression MeSH
- Cell Proliferation drug effects MeSH
- Prostate-Specific Antigen blood MeSH
- Pyrazoles therapeutic use MeSH
- Practice Guidelines as Topic MeSH
- Testosterone blood MeSH
- Thiohydantoins therapeutic use MeSH
- Tumor Burden drug effects MeSH
- United States Food and Drug Administration MeSH
- Check Tag
- Humans MeSH
- Male MeSH
- Publication type
- Research Support, Non-U.S. Gov't MeSH
- Editorial MeSH
- Geographicals
- United States MeSH
- Names of Substances
- Androgen Antagonists MeSH
- apalutamide MeSH Browser
- Benzamides MeSH
- darolutamide MeSH Browser
- enzalutamide MeSH Browser
- Phenylthiohydantoin MeSH
- Nitriles MeSH
- Prostate-Specific Antigen MeSH
- Pyrazoles MeSH
- Testosterone MeSH
- Thiohydantoins MeSH
Novel androgen deprivation agents delay metastasis in non-metastatic, castration-resistant, prostate cancer (nmCRPC). The recent regulatory guidance: considerations for metastasis-free survival endpoint in clinical trials, opens new opportunities in cell biology, medicinal chemistry and advanced imaging. Past failures are the likely result of equating tumour shrinkage to efficacy, rather than inhibition of tumour spread. In the future, the selection of anti-metastasis drug candidates will probably be based on anti-migratory rather than anti-proliferative potential. Oligometastatic cancer coupled with advanced imaging can serve as a clinical proof-of-concept model.
See more in PubMed
Beaver JA, Kluetz PG, Pazdur R. Metastasis-free Survival—a new end point in prostate cancer trials. N. Engl. J. Med. 2018;378:2458–2460. doi: 10.1056/NEJMp1805966. PubMed DOI
U.S. Department of Health and Human Services. Food and Drug Administration. Draft Guidance. Nonmetastatic, castration resistant prostate cancer: considerations for metastasis-free survival endpoint in clinical trials. 2018. https://www.fda.gov/media/117792/download
Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, et al. for the SPARTAN investigators. Apalutamide treatment and metastasis-free survival in prostate cancer. N. Engl. J. Med. 2018;378:1408–1418. doi: 10.1056/NEJMoa1715546. PubMed DOI
Hussain M, Fizazi K, Saad F, Rathenborg P, Shore N, Ferreira U, et al. Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N. Engl. J. Med. 2018;378:2465–2474. doi: 10.1056/NEJMoa1800536. PubMed DOI PMC
Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, et al. Darolutamide in nonmetastatic, castration-resistant prostate cancer. N. Engl. J. Med. 2019;380:1235–1246. doi: 10.1056/NEJMoa1815671. PubMed DOI
Brábek J, Rosel D, Fernandes M. Pragmatic medicine in solid cancer: a translational alternative to precision medicine. Onco Targets Ther. 2016;9:1839–1855. doi: 10.2147/OTT.S103832. PubMed DOI PMC
Gandalovičová A, Rosel D, Fernandes M, Veselý P, Heneberg P, Čermák V, et al. Migrastatics-anti-metastatic and anti-invasion drugs: promises and challenges. Trends Cancer. 2017;3:391–406. doi: 10.1016/j.trecan.2017.04.008. PubMed DOI PMC
Weichselbaum RR, Hellman S. Oligometastases revisited. Nat. Rev. Clin. Oncol. 2011;8:378–382. doi: 10.1038/nrclinonc.2011.44. PubMed DOI
Hong JC, Salama JK. The expanding role of stereotactic body radiation therapy in oligometastatic solid tumors: What do we know and where are we going? Cancer Treat. Rev. 2017;52:22–32. doi: 10.1016/j.ctrv.2016.11.003. PubMed DOI
Leung L, Niculescu-Duvaz D, Smithen D, Lopes F, Callens C, McLeary R, et al. Anti-metastatic inhibitors of lysyl oxidase (LOX): design and structure-activity relationships. J. Med. Chem. 2019;62:5863–5884. doi: 10.1021/acs.jmedchem.9b00335. PubMed DOI PMC
Gerwing M, Herrmann K, Helfen A, Schliemann C, Berdel WE, Eisenblätter M, et al. The beginning of the end for conventional RECIST—novel therapies require novel imaging approaches. Nat. Rev. Clin. Oncol. 2019;16:442–458. doi: 10.1038/s41571-019-0169-5. PubMed DOI
Fendler Wolfgang P., Calais Jeremie, Eiber Matthias, Flavell Robert R., Mishoe Ashley, Feng Felix Y., Nguyen Hao G., Reiter Robert E., Rettig Matthew B., Okamoto Shozo, Emmett Louise, Zacho Helle D., Ilhan Harun, Wetter Axel, Rischpler Christoph, Schoder Heiko, Burger Irene A., Gartmann Jeannine, Smith Raven, Small Eric J., Slavik Roger, Carroll Peter R., Herrmann Ken, Czernin Johannes, Hope Thomas A. Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer. JAMA Oncology. 2019;5(6):856. doi: 10.1001/jamaoncol.2019.0096. PubMed DOI PMC
Hoffmann Manuela A., Wieler Helmut J., Baues Christian, Kuntz Nicholas J., Richardsen Ines, Schreckenberger Mathias. The Impact of 68Ga-PSMA PET/CT and PET/MRI on the Management of Prostate Cancer. Urology. 2019;130:1–12. doi: 10.1016/j.urology.2019.04.004. PubMed DOI
Brábek J, Fernandes M. Affordable cancer care. Lancet Oncol. 2012;1:32–33. PubMed
